Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies.
It is a $12.7B healthcare company. Revenue grew 0.8% over the last year, it keeps 3¢ of every dollar of sales as profit, and its net debt equals ~2.5 years of free cash flow. It trades at 182.1× earnings.
- Website
- iconplc.com
- Employees
- 40 100
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong quality; Profitability, Health and Moat lag behind.
Valuation67
- P/E vs own history67th pct · 5/25
- FCF yield8.1% · 25/25
- P/S1.5x · 25/25
- EV/EBITDA21.7x · 12/25
Growth63
- Revenue CAGR10.8% · 20/25
- Net income CAGR8.7% · 12/25
- EPS CAGR ~5Y4.8% · 6/25
- Fwd implied growth1147.9% · 25/25
Profitability21
- ROIC1.8% · 5/25
- ROE0.8% · 5/25
- Net margin2.6% · 6/25
- Operating margin3.9% · 5/25
Health38
- Altman Z1.88 · 10/25
- Current ratio0.95 · 6/25
- Interest coverage2.3x · 10/25
- Net cash / debtD/A 16% · 12/25
Quality90
- Piotroski F6/9 · 15/25
- Beneish M-2.68 · 25/25
- FCF conversion481% · 25/25
- Margin stabilityσ 2.7% · 25/25
Moat43
- ROIC >12% years0/5 yrs · 0/25
- Median gross margin28.7% · 6/25
- FCF-positive years5/5 yrs · 25/25
- Worst-year net marginworst 2.6% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2024FinancialBest year on record$727M net income
- FY2021FinancialProfitable every year on record5 consecutive profitable years in our data
- FY2021FinancialRevenue already above $1B$5.48B in first reported year
- FY2021FinancialPositive free cash flow every year since5-year streak
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
No standout strengths in the available data.
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+0.8% YoY
- Profitable — makes more than it spends$214M FY2025
- Profit growing — earnings are higher than last year-22.0% YoY
- Generates cash — cash left after running and investing$1.03B FY2025
- Debt under control — could handle its obligations~2.5y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$12.7B market cap
- Not printing shares — share count not ballooning — you keep your slice+16.0% shares over ~5y
- Proven track record — years of profitability behind it5/5 profitable years
- Financially stable — balance sheet not near distressAltman Z 1.9 — grey
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 182.1
Peer comparisonICON plc vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| ICLR this company | $12.7B | 182.1 | +0.8% | 2.6% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: ICLR vs LLY · ICLR vs JNJ · ICLR vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2021–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/ICLR
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of ICLR on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $164.17 · market cap $12.7B.